Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT00145197 Completed - Breast Cancer Clinical Trials

Reducing Underuse of Early-Stage Breast Cancer Treatment in Minority Communities

Start date: January 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if a physician-centered intervention will help women with early stage breast cancer receive appropriate treatment.

NCT ID: NCT00144898 Completed - Breast Cancer Clinical Trials

GF-GS 01: Comparing Conventional Axillary Dissection Versus Sentinel Node Resection in Clinically Node-negative Operable Breast Cancer

Start date: July 2003
Phase: Phase 3
Study type: Interventional

Sentinel node resection appears as a promising advancement in the surgical treatment of breast cancer. The GF-GS 01 study, sponsored by a National Hospital Research Program, compares this new surgical method with a classical method in patients having a negative sentinel node. The duration of the follow-up is 5 years.

NCT ID: NCT00143390 Completed - Breast Neoplasms Clinical Trials

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Start date: April 2005
Phase: Phase 3
Study type: Interventional

To verify the non-inferiority of exemestane compared to anastrozole in time to tumor progression (TTP), the primary efficacy endpoint, in postmenopausal women with advanced/recurrent breast cancer.

NCT ID: NCT00141635 Completed - Breast Neoplasms Clinical Trials

Implementation of Quality of Life Diagnostics and Therapy

Start date: December 2002
Phase: Phase 1
Study type: Observational

Implementation and Evaluation of Implementation of Quality of Life Diagnostics and Therapy in Individual Patients with Breast Cancer. A prospective study including 170 patients, 5 clinics and 38 general practitioners as coordinating doctors for quality of life therapies. Correlational study including several comparisons such as patients and their doctors.

NCT ID: NCT00140738 Completed - Neoplasms, Breast Clinical Trials

Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer

Start date: March 10, 2005
Phase: Phase 1
Study type: Interventional

Patients will receive a maximum of 18 injections of dHER2 vaccine in a treatment schedule that will last for up to about a year, and thereafter there will be a follow-up period of about one more year.

NCT ID: NCT00140075 Completed - Adenocarcinoma Clinical Trials

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Start date: November 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.

NCT ID: NCT00136539 Completed - Breast Cancer Clinical Trials

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Start date: March 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.

NCT ID: NCT00135018 Completed - Breast Cancer Clinical Trials

Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer

Start date: February 2006
Phase: Phase 2
Study type: Interventional

This study will investigate whether cyclooxygenase inhibition with celecoxib will add any benefit to preoperative chemotherapy alone for breast cancer patients.

NCT ID: NCT00134680 Completed - Clinical trials for Metastatic Breast Cancer

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

Start date: January 2000
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®) has on breast cancer. The United States (US) Food and Drug Administration has approved both letrozole and Herceptin for the treatment of advanced breast cancer. Doctors hope that the combination will work better than either drug alone.

NCT ID: NCT00131963 Completed - Breast Cancer Clinical Trials

A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel

Start date: October 2003
Phase: N/A
Study type: Observational

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well doxorubicin, cyclophosphamide, and/or paclitaxel work in treating women with nonmetastatic breast cancer.